Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes

Basit Öğe Kaydı
dc.contributor.authorOdabas, Faruk Omer
dc.contributor.authorUca, Ali Ulvi
dc.contributor.authorAkdag, Turan
dc.contributor.authorDemirdogen, Filiz
dc.contributor.authorAltas, Mustafa
dc.contributor.authorTokgoz, Osman Serhat
dc.date.accessioned2024-02-23T14:32:09Z
dc.date.available2024-02-23T14:32:09Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractBackground: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. Objective: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. Methods: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. Results: SESN2 levels were significantly lower in MS patients than in controls (z:-3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507-10.494 and p=0.013]. Conclusions: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS.en_US
dc.identifier.doi10.1590/0004-282X-ANP-2021-0202
dc.identifier.endpage404en_US
dc.identifier.issn0004-282X
dc.identifier.issn1678-4227
dc.identifier.issue4en_US
dc.identifier.pmid35195231en_US
dc.identifier.scopus2-s2.0-85131105565en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage399en_US
dc.identifier.urihttps://doi.org/10.1590/0004-282X-ANP-2021-0202
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15516
dc.identifier.volume80en_US
dc.identifier.wosWOS:000759808700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Arquivos Neuro- Psiquiatriaen_US
dc.relation.ispartofArquivos De Neuro-Psiquiatriaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectSestrinsen_US
dc.subjectApoptosisen_US
dc.subjectBiomarkersen_US
dc.subjectInflammationen_US
dc.subjectOxidative Stressen_US
dc.titlePossible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu